Joshua Robert Giguere

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 7 CIPO patents and 2 EPO patents. Top assignees: Rhodes Technologies, Boston Medical Center Corporation, Boston University. Active years: 2014-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joshua Robert Giguere. Retrieved from https://idiyas.com/inventor/joshua-robert-giguere

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 7

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 36(Granted Patents)

Location History:

Coventry, RI (US) (2018 - 2020)
Sharon, MA (US) (2014 - 2022)

Company Filing History:

Boston Medical Center Corporation

Northeastern University

patents

where one patent can have more than one assignee

Years Active: 2014-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11390627 - Process for improved opioid synthesis (2022-07-19),

2. 10844072 - Process for improved oxycodone synthesis (2020-11-24),

3. 10428079 - Process for improved oxycodone synthesis (2019-10-01),

4. 10316042 - Process for improved opioid synthesis (2019-06-11),

5. 10314810 - Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics (2019-06-11),

6. 10258600 - Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics (2019-04-16),

7. 10202396 - Process for improved opioid synthesis (2019-02-12),

8. 10189852 - Process for improved oxymorphone synthesis (2019-01-29),

9. 9938285 - Process for improved oxymorphone synthesis (2018-04-10),

10. 9932348 - Process for improved oxycodone synthesis (2018-04-03),

11. 9657030 - Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof (2017-05-23),

12. 9624232 - Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof (2017-04-18),

13. 9593124 - Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof (2017-03-14),

14. 9499557 - Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof (2016-11-22),

15. 9309258 - Process for N-dealkylation of tertiary amines (2016-04-12),

Title: Innovations of Joshua Robert Giguere

Introduction

Joshua Robert Giguere is a notable inventor based in Sharon, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of opioids. With a total of 17 patents to his name, Giguere's work has had a profound impact on the development of new medical treatments.

Latest Patents

Giguere's latest patents include a process for improved opioid synthesis. This involves compounds and compositions that serve as starting materials or intermediate materials in the preparation of opioids, such as oxycodone base and oxycodone salt. The processes outlined in his patents detail the preparation of these compounds and their applications in the formulation of active pharmaceutical ingredients (APIs) and pharmaceutical dosage forms. Additionally, he has developed a process for improved oxycodone synthesis, which includes a hydrogenation step of a 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.

Career Highlights

Throughout his career, Giguere has worked with prominent organizations, including Rhodes Technologies and Boston University. His experience in these institutions has allowed him to refine his expertise in pharmaceutical development and innovation.

Collaborations

Giguere has collaborated with notable colleagues, including Keith Edward McCarthy and Helge Alfred Reisch. These partnerships have contributed to the advancement of his research and the successful development of his patented processes.

Conclusion

Joshua Robert Giguere's contributions to opioid synthesis and pharmaceutical innovation highlight his importance in the field. His extensive patent portfolio and collaborations with esteemed colleagues underscore his commitment to advancing medical science.

Profile summary based on public USPTO records.